Company intelligence / Profile preview

Vitruvian Clinical Research

Addison, Texas, United Stateslinkedin.com ↗

Ownership: Private
Development stage: Commercial

Overview

The company’s lead assets are preclinical-stage vaccines targeting amyloid beta and tau proteins for Alzheimer’s disease. No active clinical trials are currently registered. The company states their current focus is on Alzheimer's Disease utilizing a breakthrough Therapeutic Vaccine which targets ABeta and TAU and an AD Biomarker for early stage detection. YM7555 (APP x TAU) for Alzheimer Disease is in preclinical stage. No published clinical results yet.

Therapeutic areas: Neurology
Modalities: Therapeutic vaccineDNA vaccinemRNA vaccine
Industry: Biotech

Partnerships

Key partners in biotech/pharmaceutical industries mentioned generically

Beyond the preview

Go deeper on Vitruvian Clinical Research.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vitruvian Clinical Research.

Explore the full profile